![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/PFIZER.png)
Share the post "Pfizer ‘s Q2 Report: Revenue Rises by 2.33% YoY"
Highlights
- The presented financial data is Standalone to provide a comprehensive overview of the company performance.
- Sales over the Year and quarter: The company experienced a substantial growth of 2.33 % in the past year, substantial increase in net sales/revenue by 4.57 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 19.41 %. Marginal increase in other income during this quarter, up by 2.94%.
- Profit over the Year and quarter: Significant improvement in profitability for Pfizer Limited. Notable increase of 6.3 % in net profit Year to Year, Pfizer Limited’s profitability increased by 5.07 % in this quarter.
- EPS over the Year and quarter: EPS increased by 6.30 % Year to Year. EPS increased by 5.07 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 575.21 Cr | Rs. 562.86 Cr | Rs. 588.59 Cr | + 4.57 % | + 2.33 % |
| Expenses | Rs. 392.6 Cr | Rs. 385.37 Cr | Rs. 399.34 Cr | + 3.63 % | + 1.72 % |
| Operating Profit | Rs. 182.61 Cr | Rs. 177.49 Cr | Rs. 189.25 Cr | + 6.63 % | + 3.64 % |
| OPM % | 31.75 % | 31.53 % | 32.15 % | + 0.62 % | + 0.4 % |
| Other Income | Rs. 36.07 Cr | Rs. 41.84 Cr | Rs. 43.07 Cr | + 2.94 % | + 19.41 % |
| Interest | Rs. 2.73 Cr | Rs. 2.11 Cr | Rs. 2.1 Cr | -0.47 % | -23.08 % |
| Depreciation | Rs. 15.43 Cr | Rs. 14.6 Cr | Rs. 14.99 Cr | + 2.67 % | -2.85 % |
| Profit before tax | Rs. 200.52 Cr | Rs. 202.62 Cr | Rs. 215.23 Cr | + 6.22 % | + 7.34 % |
| Tax % | 25.71 % | 25.62 % | 26.43 % | + 0.81 % | + 0.72 % |
| Net Profit | Rs. 148.96 Cr | Rs. 150.71 Cr | Rs. 158.35 Cr | + 5.07 % | + 6.3 % |
| EPS in Rs | Rs. 32.56 | Rs. 32.94 | Rs. 0 | 0 % | 0 % |
Today, we’re looking at Pfizer Limited’s financial performance for the Q2(Sep 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 2.33 %. However, it did see a marginal increase of 4.57 % from the previous quarter. Expenses ticked up slightly by 3.63 % quarter-on-quarter, aligning with the annual rise of 1.72 %. Operating profit, while up 3.64 % compared to last year, faced a quarter-on-quarter increase of 6.63 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 0.4 %, but an expansion of 0.62 % sequentially. Other income rose by 2.94 % compared to the last quarter, despite an annual growth of 19.41 %. Interest expenses dropped significantly by -0.47 % from the previous quarter, yet the year-over-year decrease remains at a moderate -23.08 %. Depreciation costs climbed by 2.67 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -2.85 %. Profit before tax grew annually by 7.34 % but saw an increase from the preceding quarter by 6.22 %.
Tax expenses as a percentage of profits increased slightly by 0.72 % compared to last year, with a more notable quarter-on-quarter increase of 0.81 %. Net profit rose by 6.3 % year-on-year but experienced a 5.07 % expansion from the last quarter. In summary, Pfizer Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 575.21 Cr | Rs. 562.86 Cr | Rs. 588.59 Cr | + 4.57 % | + 2.33 % |
| Expenses | Rs. 392.6 Cr | Rs. 385.37 Cr | Rs. 399.34 Cr | + 3.63 % | + 1.72 % |
| Operating Profit | Rs. 182.61 Cr | Rs. 177.49 Cr | Rs. 189.25 Cr | + 6.63 % | + 3.64 % |
| Net Profit | Rs. 148.96 Cr | Rs. 150.71 Cr | Rs. 158.35 Cr | + 5.07 % | + 6.3 % |
| EPS in Rs | Rs. 32.56 | Rs. 32.94 | Rs. 0 | 0 % | 0 % |
In reviewing Pfizer Limited’s 2024-25(Q2) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 2.33 % year-on-year growth, however, there was a minor increase of 4.57 % from the previous quarter. Expenses rose by 1.72 % compared to the previous year, with a 3.63 % increase quarter-on-quarter. Operating Profit surged by 3.64 % annually, and saw a 6.63 % increase from the last quarter.
Net Profit showed yearly increase of 6.3 %, and experienced a 5.07 % increase from the previous quarter. In essence, while Pfizer Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
3
3-Year Profit
5
5-Year Profit
10
10-Year Profit
5,203
Current Price
23,821
Market Cap
Upon examining the financial data for BSE code 500680, it becomes clear that the company achieved a notable five-year profit of 5 percents, which impressively increased to 3 percents in the three-year window. This upward trajectory, however, has been overshadowed by the latest trailing twelve-month (TTM) figures, which indicate a concerning loss of 15 percents. This financial loss is further compounded by the fact that the company has not recorded any sales across any of the timeframes under consideration. Such an unusual situation might suggest that the company operates under an unconventional business model, which could potentially carry higher risks. In terms of stock performance, the company’s stock price has seen a decline, falling from 5 percents over the five-year period to just 33 percents in the last year. The ten-year average stock price, which sits at 12 percents, highlights long-term volatility, casting doubt on the company's ability to sustain its market position over time. This warrants further investigation into the factors driving these fluctuations.
The company has a market capitalization of ₹23,821 crore and is currently trading at ₹5,203 per share. Historically, the stock has fluctuated within a range of ₹6,453 / 3,895, reflecting both the opportunities and risks that investors perceive in the company. The P/E ratio, at 155, is relatively high, suggesting that the market has priced in substantial future growth or is willing to pay a premium for the company’s current earnings. The book value per share stands at ₹302, which reflects the net asset value of the company divided by the number of outstanding shares. The dividend yield is 0.67%, providing shareholders with a consistent return on their investment. ROCE is 27.2%, indicating how well the company is using its capital to generate profits, while ROE at 19.8% highlights the returns generated from shareholders' equity. The debt-to-equity ratio is 0.00, signaling low financial leverage, which is typically seen as a positive indicator of financial health. However, the company’s negative net cash flow of ₹63.7 crore might raise concerns about its cash generation capabilities or capital expenditures. With a Piotroski score of 8.00, the company's financial stability is evaluated on several factors. Finally, the Graham Number, at ₹826, provides an estimate of the stock’s intrinsic value, while the Price-to-Book (P/B) ratio of 17.2 highlights that the stock is trading at a premium to its book value, potentially reflecting positive market sentiment or overvaluation risks.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/shareholding/meeting-background-yfnpez33riesb0vr.jpg)
